# Concept: Total Capitalised research and development expense for bioindustry

## Bilingual Labels
- **EN**: Total Capitalised research and development expense for bioindustry
- **KO**: 자산화된 연구개발비, 바이오 제약, 총액

- **ID**: dart:GrossCapitalisedResearchAndDevelopmentExpenseForBioindustry

## Reported Numerical Facts

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 252,749,745,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 243,308,510,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 252,749,745,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 243,308,510,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 60,565,393,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 82,998,796,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 60,565,393,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 82,998,796,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 9,385,679,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 9,328,641,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 3,278,685,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 3,257,026,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 24,381,913,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 28,882,338,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 19,732,991,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 23,367,121,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2025-03-31**
  - **Value**: 9,442,716,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 827,352,351,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 813,705,436,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 829,297,477,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 815,650,562,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 137,959,832,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 142,611,879,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 137,959,833,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 142,611,879,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 126,857,630,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 131,895,409,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 126,857,630,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 131,895,409,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 12,906,718,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 7,395,698,000 (decimals: -3)

### **Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 12,906,718,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 7,395,698,000 (decimals: -3)

### **Context (Labels): Consolidated and separate financial statements [axis]: Consolidated [member]**
<!-- Context (IDs): ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:ConsolidatedMember -->
- **Period: 2024-12-31**
  - **Value**: 1,452,159,261,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 1,460,126,707,000 (decimals: -3)

### **Context (Labels): Consolidated and separate financial statements [axis]: Separate [member]**
<!-- Context (IDs): ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis: ifrs-full:SeparateMember -->
- **Period: 2024-12-31**
  - **Value**: 1,443,348,472,000 (decimals: -3)
- **Period: 2025-03-31**
  - **Value**: 1,450,485,001,000 (decimals: -3)

## Accounting Standard References
- **Standard**: 제약․바이오 기업의 연구개발비 회계처리 관련 감독지침 nan, Paragraph: nan

---
*Source Document: entity00413046_2025-03-31.xbrl*
## Embeddable Text (for FAISS)
```text
Concept: Total Capitalised research and development expense for bioindustry
Bilingual Labels
 EN: Total Capitalised research and development expense for bioindustry
 KO: 자산화된 연구개발비, 바이오 제약, 총액
 ID: dart:GrossCapitalisedResearchAndDevelopmentExpenseForBioindustry
Reported Numerical Facts
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 252,749,745,000 (decimals: 3)
 Period: 20250331
   Value: 243,308,510,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 252,749,745,000 (decimals: 3)
 Period: 20250331
   Value: 243,308,510,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 60,565,393,000 (decimals: 3)
 Period: 20250331
   Value: 82,998,796,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:CancerTreatmentOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 60,565,393,000 (decimals: 3)
 Period: 20250331
   Value: 82,998,796,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 9,385,679,000 (decimals: 3)
 Period: 20250331
   Value: 9,328,641,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 3,278,685,000 (decimals: 3)
 Period: 20250331
   Value: 3,257,026,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 24,381,913,000 (decimals: 3)
 Period: 20250331
   Value: 28,882,338,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 19,732,991,000 (decimals: 3)
 Period: 20250331
   Value: 23,367,121,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:ChemicalMedicines2OfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20250331
   Value: 9,442,716,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 827,352,351,000 (decimals: 3)
 Period: 20250331
   Value: 813,705,436,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 829,297,477,000 (decimals: 3)
 Period: 20250331
   Value: 815,650,562,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 137,959,832,000 (decimals: 3)
 Period: 20250331
   Value: 142,611,879,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForImmuneDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 137,959,833,000 (decimals: 3)
 Period: 20250331
   Value: 142,611,879,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 126,857,630,000 (decimals: 3)
 Period: 20250331
   Value: 131,895,409,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingAmortizedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 126,857,630,000 (decimals: 3)
 Period: 20250331
   Value: 131,895,409,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 12,906,718,000 (decimals: 3)
 Period: 20250331
   Value: 7,395,698,000 (decimals: 3)
Context (Labels): Categories of new drugs for bioindustry [axis]: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Classes of intangible assets other than goodwill [axis]: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): dart:CategoriesOfNewDrugsForBioindustryAxis: entity00413046:TreatmentForOtherDiseasesOfCategoriesOfNewDrugsForBioindustryMemberOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ClassesOfIntangibleAssetsOtherThanGoodwillAxis: entity00413046:DevelopmentCostsBeingDevelopedOfDevelopmentCostsOfResearchAndDevelopmentExpenseForBioindustryTableOfMember and ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 12,906,718,000 (decimals: 3)
 Period: 20250331
   Value: 7,395,698,000 (decimals: 3)
Context (Labels): Consolidated and separate financial statements [axis]: Consolidated [member]
<! Context (IDs): ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:ConsolidatedMember >
 Period: 20241231
   Value: 1,452,159,261,000 (decimals: 3)
 Period: 20250331
   Value: 1,460,126,707,000 (decimals: 3)
Context (Labels): Consolidated and separate financial statements [axis]: Separate [member]
<! Context (IDs): ifrsfull:ConsolidatedAndSeparateFinancialStatementsAxis: ifrsfull:SeparateMember >
 Period: 20241231
   Value: 1,443,348,472,000 (decimals: 3)
 Period: 20250331
   Value: 1,450,485,001,000 (decimals: 3)
Accounting Standard References
 Standard: 제약․바이오 기업의 연구개발비 회계처리 관련 감독지침 nan, Paragraph: nan
Source Document: entity00413046_20250331.xbrl
```